Sabre Corporation (SABR)
NASDAQ: SABR · Real-Time Price · USD
2.930
-0.100 (-3.30%)
At close: Aug 1, 2025, 4:00 PM
2.900
-0.030 (-1.02%)
After-hours: Aug 1, 2025, 7:51 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 5 analysts that cover CTI BioPharma stock have a consensus rating of "Hold" and an average price target of $4.12, which forecasts a 40.61% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $6.10.
Price Target: $4.12 (+40.61%)
Analyst Consensus: Hold
* Price targets were last updated on Apr 16, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $3.5 | Hold | Maintains | $5 → $3.5 | +19.45% | Apr 16, 2025 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $4.5 → $6.1 | Hold → Strong Buy | Upgrades | $4.5 → $6.1 | +108.19% | Mar 4, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $4 | Hold | Reiterates | $4 | +36.52% | Feb 21, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $5 → $4 | Buy → Hold | Downgrades | $5 → $4 | +36.52% | Jan 7, 2025 |
| Bernstein | Bernstein | Hold → Sell Downgrades $3 | Hold → Sell | Downgrades | $3 | +2.39% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
3.09B
from 3.03B
Increased by 2.06%
Revenue Next Year
3.23B
from 3.09B
Increased by 4.53%
EPS This Year
0.13
from -0.73
EPS Next Year
0.38
from 0.13
Increased by 197.88%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.3B | 3.5B | 3.6B | ||
| Avg | 3.1B | 3.2B | 3.4B | ||
| Low | 2.9B | 3.0B | 3.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.3% | 14.0% | 12.3% | ||
| Avg | 2.1% | 4.5% | 4.9% | ||
| Low | -5.3% | -3.9% | -2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.22 | 0.53 | 0.68 | ||
| Avg | 0.13 | 0.38 | 0.42 | ||
| Low | 0.05 | 0.28 | 0.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 308.5% | 78.8% | ||
| Avg | - | 197.9% | 10.0% | ||
| Low | - | 121.1% | -30.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.